1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

City Of Hope's Joseph Alvarnas On CAR-T Real-World Use, Reimbursement

 
• By Mandy Jackson

City of Hope hematologist/oncologist Joseph Alvarnas shares his perspectives on how CAR-T therapies are requiring new models of health care delivery and engagement with more kinds of stakeholders, during an interview at the recent ASH annual meeting.

Joseph Alvarnas at ASH
Joseph Alvarnas, City of Hope • Source: Courtesy of ASH

Longer-term data from studies of chimeric antigen receptor T-cell (CAR-T) therapies at the American Society of Hematology (ASH) meeting Dec. 1-4 in San Diego showed that patients with hematologic malignancies who've achieved remission are maintaining their response for more than a year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By Joseph Haas

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

BeiGene Ends Anti-TIGIT Development In Lung Cancer

 
• By Joseph Haas

BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.

Merck Gets Closer To Extending Keytruda Franchise With Subcutaneous Version

 
• By Alaric DeArment

Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.

Rybrevant/Lazcluze Survival Win Could Overcome Tagrisso’s Convenience Advantage

 
• By Alaric DeArment

J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.

More from Anticancer

Epsilogen Hits Antibody Acquisition Trail With TigaTx Takeover

 
• By Kevin Grogan

Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.

BeiGene Ends Anti-TIGIT Development In Lung Cancer

 
• By Joseph Haas

BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.

AbbVie On A STEAP Learning Curve In ADCs

 
• By Andrew McConaghie

Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.